Spectral Med EBITDA vs. Gross Profit
Based on the measurements of profitability obtained from Spectral Med's financial statements, Spectral Med may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in February. Profitability indicators assess Spectral Med's ability to earn profits and add value for shareholders.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Please note, there is a significant difference between Spectral Med's value and its price as these two are different measures arrived at by different means. Investors typically determine if Spectral Med is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spectral Med's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
For Spectral Med profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Spectral Med to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Spectral Med utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Spectral Med's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Spectral Med over time as well as its relative position and ranking within its peers.
Spectral |
Spectral Med Gross Profit vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Spectral Med's current stock value. Our valuation model uses many indicators to compare Spectral Med value to that of its competitors to determine the firm's financial worth. Spectral Med is rated # 4 in ebitda category among its peers. It is rated # 2 in gross profit category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Spectral Med by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Spectral Med's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Spectral Gross Profit vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Spectral Med |
| = | (13.96 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Spectral Med |
| = | 983 K |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Spectral Med Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Spectral Med, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Spectral Med will eventually generate negative long term returns. The profitability progress is the general direction of Spectral Med's change in net profit over the period of time. It can combine multiple indicators of Spectral Med, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Spectral Medical Inc. focuses on the development and commercialization of treatment for septic shock in North America. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada. SPECTRAL MEDICAL operates under Diagnostics Research classification in Canada and is traded on Toronto Stock Exchange. It employs 18 people.
Spectral Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Spectral Med. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Spectral Med position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Spectral Med's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Spectral Med without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Options Analysis Now
Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios |
| All Next | Launch Module |
Use Investing Themes to Complement your Spectral Med position
In addition to having Spectral Med in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Outsourcing Thematic Idea Now
Outsourcing
Companies involved in providing outsourcing and staffing services to business across different domains. The Outsourcing theme has 8 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Outsourcing Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Spectral Stock
To fully project Spectral Med's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Spectral Med at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Spectral Med's income statement, its balance sheet, and the statement of cash flows.